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The adrenal incidentaloma is possibly the most common adrenal disorder encountered in 
everyday practice due to an extensive use of high-resolution cross-sectional imaging that leads 
frequently to the identification of an adrenal tumor as an incidental finding (1). These clinically 
inapparent tumors are referred to as adrenal incidentalomas to highlight their unexpected 
discovery, through a diagnostic work-up done for reasons unrelated to previous suspect of 
adrenal disease. Studies showed that an adrenal incidentaloma is found in 4% to 5% of 
abdominal CT scans (1,2) and, due to the technological improvement in imaging, frequency is 
expected to rise in the near future. 
The natural history of adrenal incidentalomas is still incompletely understood and this is an 
important gap of knowledge that hinders appropriate patient care. It is reassuring that most 
adrenal incidentalomas are benign adrenal adenomas (1, 2); however, molecular studies support 
the concept of multistep adrenocortical tumorigenesis and an evolution from benign cortical 
adenoma to adrenal carcinoma has been reported (3). Moreover, adrenal adenomas can cause 
harm to the patients through their capability of secreting autonomously cortisol (4). In 
principle, this subclinical condition of mild cortisol excess may represent a preliminary stage of 
overt Cushing’s syndrome.  
In this context, Elhassan and Colleagues strive to provide meaningful answers to several key 
questions concerning the natural history of adrenal incidentalomas: i) the risk of tumor growth 
and possible malignant transformation, ii) the risk of developing clinically overt hormone 
excess, iii) the risk of morbidity and mortality associated to autonomous cortisol secretion (5). 
They did a careful meta-analysis of the literature that is very heterogeneous as to the same 
definition of adrenal incidentaloma and, more importantly, definition of autonomous cortisol 
secretion and ascertainment of outcomes of interest.  
The first finding of the present study is that the risk of tumor growth is limited to a few cases 
and usually implies an insignificant change in size, being ≥10 mm in only 2.5% of cases, while 
malignant transformation was never observed. Cortisol autonomy was tied to an increased 
attitude to growth. These results confirm robustly, thanks to a comprehensive analysis of the 
available evidence, what was previously envisaged (6). The novel piece of information is that 
the chance of growth over time is reduced in larger tumors. Therefore, the outcome of this 
meta-analysis strongly supports the European Society of Endocrinology and the European 
Network for the study of Adrenal Tumors (ESE/ENSAT) guidelines that suggested against 
further imaging follow-up for masses <4 cm with clear benign features on imaging studies (7). 
This meta-analysis should end controversy on the need of routine imaging studies during 
follow-up (8). As the ESE/ENSAT guidelines indicate, there is an area of uncertainty for 
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masses >4 cm, given the low number of such tumors included in follow-up studies (7). The 
present results look reassuring also for this subset of tumors that, however, represent less than 
10% of adrenal incidentalomas. 
The second finding of the present study is that the risk of developing overt Cushing is 
virtually absent, while clinical inapparent cortisol autonomy may ensue in 4.3% of patients 
with non-functioning tumors. Again, this confirms and extends previous knowledge (6) and 
demonstrates clearly that autonomous cortisol secretion is not a preliminary stage of overt 
Cushing’s syndrome. This finding fits well with the reported difference in the molecular 
pathogenesis between adrenal adenomas associated with subclinical or overt cortisol excess (9). 
The value of repeating hormone work-up during follow-up of patients with adrenal 
incidentalomas remains matter of contention (8), and the present finding validates the advice of 
the ESE/ENSAT guidelines against further work-up in patients with non-functioning tumors 
(7). While the ESE/ENSAT guidelines suggested reassessment in patients with autonomous 
cortisol secretion with associated comorbidities, the present results seem to limit further the 
role of hormone testing. It has to been argued, however, that we presently do not know well 
whether the development of autonomous cortisol secretion during follow-up is tied to clinical 
consequences (4,6).  
The third and more novel finding of the present study is that both patients with non-
functioning tumors and tumors causing autonomous cortisol secretion have at baseline, and 
develop during follow-up, comorbidities and incident cardiovascular events. Given that these 
comorbidities are potentially linked to cortisol excess, it may be surprising to see that also 
patients with non-functioning tumors are affected, albeit at lower rate than patients exposed to 
autonomous cortisol secretion. It is presently unknown to what extent this may represent an 
ascertainment bias, because diseased patients are more likely to undergo imaging tests that may 
lead to the detection of an adrenal incidentaloma. Alternative explanations could be found in 
the concept of reverse causality, implying that the metabolic syndrome and/or diabetes are 
promoting adrenal tumor development (10), or in the concept of a continuum of cortisol 
secretion from normal to autonomous that escapes precise categorization due to the limitations 
of endocrine tests. Consequently, also tumors labeled as non-functioning may retain the ability 
of secreting cortisol in minimal excess.  
Elhassan and Colleagues were not able to demonstrate any association between varying 
degrees of cortisol autonomy and cardiovascular disease, and they found that the risk of dying 
for any cause, for cardiovascular disease in particular, was similar between patients with non-
functioning tumors or cortisol-secreting tumors (5). There is evidence, however, that a greater 
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degree of cortisol autonomy, heralded by higher cortisol levels after overnight dexamethasone 
suppression, is linked to increasing cardiovascular risk (4,6,7), but we need more evidence to 
understand what level of cortisol autonomy is tied to clinical consequences. Answering this 
question is key to develop adequate decision-making strategies of patients with adrenal 
incidentalomas concerning the choice between surgery and conservative management.  
To conclude, Elhassan and Colleagues provided important insights on the natural history of 
adrenal incidentalomas that help in solving controversy and informing practice (5). Further 
studies are needed to associate results of endocrine work-up with clinical phenotyping and 
patient-centered outcomes for the definition of the optimal treatment of such a frequent 
endocrine disorder. 
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